Tolbutamide (HLS 831) is an inhibitor of potassium channel, used for type II diabetes.

Tolcapone (Ro 40-7592) is a selective, potent and reversible of catechol-O-methyl transferase (COMT) inhibitor with Ki of 30 nM.

Tolfenamic Acid(Clotam) is a COX-2 inhibitor with IC50 of 0.2 μM.

Tolfenamic Acid(Clotam) is a COX-2 inhibitor with IC50 of 0.2 μM.

Tolimidone (MLR-1023) is a Lyn kinase activator and a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.

Tolimidone (MLR-1023) is a Lyn kinase activator and a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.

Tolimidone (MLR-1023) is a Lyn kinase activator and a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.

Tolinapant (ASTX660) is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP that inhibits the interactions between a SMAC-derived peptide and the BIR3 domains of XIAP (BIR3-XIAP) and cIAP1 (BIR3-cIAP1) with IC50 values less than 40 and 12 nmol/L, respectively.

Tolinapant (ASTX660) is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP that inhibits the interactions between a SMAC-derived peptide and the BIR3 domains of XIAP (BIR3-XIAP) and cIAP1 (BIR3-cIAP1) with IC50 values less than 40 and 12 nmol/L, respectively.

Tolinapant (ASTX660) is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP that inhibits the interactions between a SMAC-derived peptide and the BIR3 domains of XIAP (BIR3-XIAP) and cIAP1 (BIR3-cIAP1) with IC50 values less than 40 and 12 nmol/L, respectively.

Tolinapant (ASTX660) is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP that inhibits the interactions between a SMAC-derived peptide and the BIR3 domains of XIAP (BIR3-XIAP) and cIAP1 (BIR3-cIAP1) with IC50 values less than 40 and 12 nmol/L, respectively.

Tolmetin (Tolectin) is a nonsteroidal anti-inflammatory drug of the heterocyclic acetic acid derivative class and also exhibits analgesic and antipyretic activity.

Tolmetin (Tolectin) is a nonsteroidal anti-inflammatory drug of the heterocyclic acetic acid derivative class and also exhibits analgesic and antipyretic activity.

Tolmetin(MCN2559) is a non-steroidal anti-inflammatory drug of the arylalkanoic acids. Tolmetin sodium dihydrate is a non-steroidal antiinflammatory agent, and acts as a non-selective COX inhibitor.

Tolnaftate is a synthetic thiocarbamate used as an anti-fungal agent.

Toloxatone (MD69276, Humoryl, Perenum, Umoril) is a reversible inhibitor of monoamine oxidase A (MAO-A) with IC50 of  0.93 µM. Toloxatone is an antidepressant agent.

Toloxatone (MD69276, Humoryl, Perenum, Umoril) is a reversible inhibitor of monoamine oxidase A (MAO-A) with IC50 of  0.93 µM. Toloxatone is an antidepressant agent.

Toltrazuril is an antiprotozoal agent that acts upon Coccidia parasites.

Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.

Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.

Tomatidine Hydrochloride, a natural steroidal alkaloid, possesses potent antibacterial activity and has anti-inflammatory effects in macrophages.

Tomatidine Hydrochloride, a natural steroidal alkaloid, possesses potent antibacterial activity and has anti-inflammatory effects in macrophages.

Tomatine (Lycopersicin) is a natural glycoalkaloid with fungicidal, antimicrobial, and insecticidal properties.

Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.

Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.

Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.

Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.

Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.

Toosendanin, a triterpenoid extracted from Melia toosendan Sieb et Zucc, possesses broad biological actions from blocking neurotransmission and antibotulism to inducing cell differentiation and apoptosis.

Toosendanin, a triterpenoid extracted from Melia toosendan Sieb et Zucc, possesses broad biological actions from blocking neurotransmission and antibotulism to inducing cell differentiation and apoptosis.

Topiramate (MCN 4853, RWJ 17021) is a mutil-targeted inhibitor, including voltage-gated sodium channel andcalcium channel, AMPA/kainate receptor and carbonic anhydrase, used to treat epilepsy.

Topiramate (MCN 4853, RWJ 17021) is a mutil-targeted inhibitor, including voltage-gated sodium channel andcalcium channel, AMPA/kainate receptor and carbonic anhydrase, used to treat epilepsy.

Topiroxostat is a xanthine oxidoreductase (XOR) inhibitor and used for treatment of gout and hyperuricemia. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment.

Topiroxostat is a xanthine oxidoreductase (XOR) inhibitor and used for treatment of gout and hyperuricemia. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment.